Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm Phase3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Next Previous
Trial Profile

A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm Phase3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tarcocimab tedromer (Primary)
  • Indications Diabetic retinopathy
  • Focus Registrational; Therapeutic Use
  • Acronyms GLOW
  • Sponsors Kodiak Sciences

Most Recent Events

  • 02 Jun 2024 This trial has been completed in Czech (Global end date: 31 Aug 2023).
  • 06 Nov 2023 According to a Kodiak Sciences media release, Primary endpoint (Proportion of eyes improving 2 steps on the ETDRS Diabetic Retinopathy Severity Scale (DRSS)) has been met.
  • 06 Nov 2023 According to a Kodiak Sciences media release, data from the study were presented at the American Academy of Ophthalmology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top